Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 9/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29991596 | 0.93 | P2RX3 (0.48) | P2RX3KDM4ENPC1RAB9AL3MBTL1 | |
| SCHEMBL6864274 | 0.93 | P2RX3 (0.48) | P2RX3KDM4ENPC1RAB9AL3MBTL1 | |
| SCHEMBL14730353 | 0.93 | P2RX3 (0.48) | P2RX3KDM4ENPC1RAB9AL3MBTL1 | |
| SCHEMBL15987117 | 0.93 | P2RX3 (0.48) | P2RX3KDM4ENPC1RAB9AL3MBTL1 | |
| SCHEMBL20595262 | 0.89 | HCRTR1 (0.37) | KDM4ENPC1RAB9AL3MBTL1HCRTR1 | |
| SCHEMBL1160904 | 0.89 | HCRTR1 (0.37) | KDM4ENPC1RAB9AL3MBTL1HCRTR1 | |
| SCHEMBL21800761 | 0.85 | CYP3A4 (0.47) | KDM4E | |
| SCHEMBL21800763 | 0.85 | CYP3A4 (0.47) | KDM4E | |
| SCHEMBL16077808 | 0.84 | P2RX3 (0.49) | P2RX3L3MBTL1UCHL1BACE1MCL1 | |
| SCHEMBL29716162 | 0.84 | P2RX3 (0.46) | P2RX3KDM4ENPC1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459582-B1 | HEPATITIS C VIRUS NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2015-05-27 | — | — | EP | disclosed |
| US-8828930-B2 | Hepatitis C virus NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20120121624-A1 | HEPATITIS C VIRUS NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121624-A1 | HEPATITIS C VIRUS NS3 PROTEASE INHIBITORS | HAVCR2, GTF3C3, CTSC | P2RX3 3494/4885KDM4E 3040/4885NPC1 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.